Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Medipal to Take on Akalux Distribution in Japan, Rakuten’s Photoimmunotherapy
January 13, 2021
- Nobelpharma Launches China Subsidiary
January 13, 2021
- Health Damages Linked to Kobayashi Kako Issue Rise to 210
January 13, 2021
- SymBio’s Anticancer Agent Treakisym Now Available in RTD Formulation
January 13, 2021
- Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
- Drug Makers, Wholesalers Boost WFH as Japan Declares Second Emergency
January 12, 2021
- Takeda Rolls Out Early Training Program for Young Management Candidates
January 12, 2021
- Meiji’s Belumosudil Enters Japan PI Study for cGVHD
January 12, 2021
- Japan Ethical Drug Sales Down 6.1% in November: Crecon
January 12, 2021
- Keytruda Tops in 2020 Drug Ranking for 2 Years in Row; Sales of 3 Cancer Meds Exceed 100 Billion Yen
January 8, 2021
- Keytruda Best-Selling Drug in December: Encise
January 8, 2021
- ASKA Grants Exclusive Chinese Sales Rights for Altat to Local Firm
January 8, 2021
- LEO Pharma Earns Approval for Dovobet Foam Version
January 7, 2021
- Relugolix Now Available for Advanced Prostate Cancer in US
January 7, 2021
- Mirabegron Gets FDA’s Priority Review for Pediatric NDO: Astellas
January 7, 2021
- Kyowa Kirin Begins Japan PIII for Bardoxolone in ADPKD
January 7, 2021
- Fujifilm to Set Up Viral-Vector Contract Manufacturing Hub in Boston Area
January 6, 2021
- Sosei Regains Global Rights to Muscarinic Agonist Programs from AbbVie, CEO Says It’s Not Bad News
January 6, 2021
- Meiji Pharma Fortifies US Foothold with New Subsidiary
January 6, 2021
- JCR Inks Domestic Production Deal for AstraZeneca COVID-19 Vaccine Solution
January 6, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…